A new independent 46 page research with title ‘Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 184.108.40.206) – Pipeline Review, H2 2017’guarantees you will remain better informed than your competition. The study covers geographic analysis that includes regions and important players/vendors such as Conatus Pharmaceuticals Inc, New World Laboratories Inc, Novartis AG, etc.
According to the recently published report ‘Caspase 6 – Pipeline Review, H2 2017’; Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 220.127.116.11) pipeline Target constitutes close to 5 molecules. Out of which approximately 3 molecules are developed by companies and remaining by the universities/institutes.
Caspase-6 is an enzyme encoded by the CASP6 gene.
It is involved in the activation cascade of caspases responsible for apoptosis execution. It cleaves poly (ADP-ribose) polymerase.
The report ‘Caspase 6 – Pipeline Review, H2 2017’ outlays comprehensive information on the Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 18.104.22.168) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.
It also reviews key players involved in Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 22.214.171.124) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II and Preclinical stages are 1 and 2 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Central Nervous System, Gastrointestinal, Cardiovascular, Genito Urinary System And Sex Hormones, Immunology, Infectious Disease, Oncology and Respiratory which include indications Huntington Disease, Alzheimer’s Disease, Autoimmune Hepatitis, Colorectal Cancer, Hepatitis C, Hepatocellular Carcinoma, Liver Cirrhosis, Liver Failure (Hepatic Insufficiency), Liver Fibrosis, Liver Transplant Rejection, Non Alcoholic Fatty Liver Disease (NAFLD), Non-Alcoholic Steatohepatitis (NASH), Pancreatic Islet Transplant Rejection, Portal Hypertension, Primary Sclerosing Cholangitis, Pulmonary Fibrosis and Renal Failure.
Get customization & check discount for report @ https://www.htfmarketreport.com/request-discount/852556-caspase-6-apoptotic-protease-mch-2-or-casp6-or-ec-3-4-22-59-pipeline-review-1
– The report provides a snapshot of the global therapeutic landscape for Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 126.96.36.199)
– The report reviews Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 188.8.131.52) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
– The report reviews key players involved in Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 184.108.40.206) targeted therapeutics and enlists all their major and minor projects
– The report assesses Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 220.127.116.11) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
– The report summarizes all the dormant and discontinued pipeline projects
– The report reviews latest news and deals related to Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 18.104.22.168) targeted therapeutics
Buy this report @ https://www.htfmarketreport.com/buy-now?format=1&report=852556
Reasons to buy
– Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
– Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
– Identify and understand the targeted therapy areas and indications for Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 22.214.171.124)
– Identify the use of drugs for target identification and drug repurposing
– Identify potential new clients or partners in the target demographic
– Develop strategic initiatives by understanding the focus areas of leading companies
– Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
– Devise corrective measures for pipeline projects by understanding Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 126.96.36.199) development landscape
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Companies Mentioned in the Report
Conatus Pharmaceuticals Inc
New World Laboratories Inc
View Detailed Table of Content @ https://www.htfmarketreport.com/reports/852556-caspase-6-apoptotic-protease-mch-2-or-casp6-or-ec-3-4-22-59-pipeline-review-1
Thanks for reading this article, you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.
CRAIG FRANCIS (PR & Marketing Manager)
Ph: +1 (206) 317 1218